Autoantibodies Are Early Diabetes Warning Signs
|
By LabMedica International staff writers Posted on 09 Mar 2015 |
Detection of autoantibodies directed against pancreatic islet cells can be used to predict the likelihood of a child developing type I diabetes.
Investigators at Lund University (Sweden) recruited 8,503 participants in the TEDDY (The Environmental Determinants of Diabetes in the Young) study to take part in their autoantibody experiment. The TEDDY study, funded by the [US] National Institutes of Health, involved 8,600 children from Sweden, the USA, Finland, and Germany, who showed an increased hereditary risk of type I diabetes, detected at birth through tests on umbilical cord blood.
Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8, and DR3/3) from the TEDDY group were prospectively followed with standardized autoantibody assessments quarterly throughout the first four years of life and then semiannually thereafter. The Lund University researchers reported that 6.5% of the participating children had their first autoantibody before the age of six. In 44% of cases, they only had an autoantibody against insulin (IAA). Most of them had this by the age of one to two years. In 38% of cases, GAD65 autoantibodies (GADA) were detected. The numbers increased until the age of two and then remained constant. In 14% of cases both autoantibodies were found at the same time, with a peak at the age of two to three.
The investigators concluded from the results that there were three ways to predict development of type I diabetes: 1) if the autoantibody first discovered attacked insulin (IAA); 2) if the first autoantibody targeted GAD65 (GADA), a protein inside the insulin-producing cells; or 3) if both autoantibodies were first found together.
"In the TEDDY study we have found that autoantibodies often appear during the first few years of life", said contributing author Dr. Åke Lernmark, professor of experimental diabetes at Lund University. "If a second autoantibody is detected later, then the person will get diabetes - but it may take up to 20 years. In TEDDY, 40% of these children had already developed diabetes. It is possible that there are two different diseases involved. Perhaps one virus triggers the autoantibodies against insulin and another one the autoantibodies against GAD65."
The study was published in the February 10, 2015, online edition of the journal Diabetologia.
Related Links:
Lund University
Investigators at Lund University (Sweden) recruited 8,503 participants in the TEDDY (The Environmental Determinants of Diabetes in the Young) study to take part in their autoantibody experiment. The TEDDY study, funded by the [US] National Institutes of Health, involved 8,600 children from Sweden, the USA, Finland, and Germany, who showed an increased hereditary risk of type I diabetes, detected at birth through tests on umbilical cord blood.
Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8, and DR3/3) from the TEDDY group were prospectively followed with standardized autoantibody assessments quarterly throughout the first four years of life and then semiannually thereafter. The Lund University researchers reported that 6.5% of the participating children had their first autoantibody before the age of six. In 44% of cases, they only had an autoantibody against insulin (IAA). Most of them had this by the age of one to two years. In 38% of cases, GAD65 autoantibodies (GADA) were detected. The numbers increased until the age of two and then remained constant. In 14% of cases both autoantibodies were found at the same time, with a peak at the age of two to three.
The investigators concluded from the results that there were three ways to predict development of type I diabetes: 1) if the autoantibody first discovered attacked insulin (IAA); 2) if the first autoantibody targeted GAD65 (GADA), a protein inside the insulin-producing cells; or 3) if both autoantibodies were first found together.
"In the TEDDY study we have found that autoantibodies often appear during the first few years of life", said contributing author Dr. Åke Lernmark, professor of experimental diabetes at Lund University. "If a second autoantibody is detected later, then the person will get diabetes - but it may take up to 20 years. In TEDDY, 40% of these children had already developed diabetes. It is possible that there are two different diseases involved. Perhaps one virus triggers the autoantibodies against insulin and another one the autoantibodies against GAD65."
The study was published in the February 10, 2015, online edition of the journal Diabetologia.
Related Links:
Lund University
Latest Clinical Chem. News
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
- Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
Channels
Molecular Diagnostics
view channel
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more
Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more
Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Cancer screening is intended to reduce mortality, but policy decisions often depend on early indicators that may not fully reflect true survival benefit. The emergence of blood-based tests capable of detecting... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read moreMicrobiology
view channel
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read more
New AMR Assay Supports Rapid Infection Control Screening in Hospitals
As antimicrobial resistance spreads worldwide, healthcare-associated infections are placing a growing burden on hospitals, increasing the need for faster and broader diagnostic solutions.... Read morePathology
view channel
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read moreTechnology
view channel
AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read moreIndustry
view channel
New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays
Eurobio Scientific (Les Ulis, France) has signed a distribution agreement with Canhelp Genomics (Hangzhou, China) to broaden availability of the Canhelp‑UCa and Canhelp‑Origin assays. The agreement extends... Read more








